.gif)
Jubilant DraxImage Inc. (DraxImage), a subsidiary of Jubilant Life Sciences and Cyclopharm Limited (CYC), provider of innovative solutions in nuclear medicine signed a term sheet to market and distribute Technegas in the United States. DraxImage will assist CYC with the development and financing of the phase III clinical trials for Technegas, and any other steps required to file for and obtain US FDA approval.
The execution of this term sheet demonstrates DraxImage’s commitment to invest in and grow the sustainability of ventilation/perfusion imaging in the US and our continued passion to bring innovative products that enable physicians to deliver high quality diagnostics to their patients.
Subscribe to PharmaTutor News Alerts by Email >>
